Rhizen Pharmaceuticals S.A. announces a scientific presentation on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor in T-cell Lymphomas at the 18th Congress of European Hematology Association, 13-16 June 2013
June 12, 2013 05:08 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, June 12, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a scientific poster
presentation on the therapeutic potential of its novel,...